Research Article

Intratumoral TLR-4 Agonist Injection Is Critical for Modulation of Tumor Microenvironment and Tumor Rejection

Figure 1

Peritumoral infiltrate in mice subcutaneously injected with B16F10. (a) H/E paraffin skin section of B16F10, day 9 of tumor grown in mice. (b) H/E section of PBS injection site in control mice without tumor. (c) H/E frozen section of injected tumor, used as basis to immunofluorescence. (d), (e), and (f) Immunofluorescence (Red) staining of frozen tumor to CD8 (d), CD11c (e), and CD4 (f); counterstained whit Hoechst. (g) and (h) Immunoflouresce staining of frozen tumor to Foxp3, day 6 of tumor grown (g) and day 9 of tumor grown. (i) Tumor measurements over time. (j) Number of lymphocytes per field, at each tumor measurement timepoint. Data are representative of five different experiments, with 𝑁 = 4 mice per group.
926817.fig.001a
(a)
926817.fig.001b
(b)
926817.fig.001c
(c)
926817.fig.001d
(d)
926817.fig.001e
(e)
926817.fig.001f
(f)
926817.fig.001g
(g)
926817.fig.001h
(h)
926817.fig.001i
(i)
926817.fig.001j
(j)